Screener
Ultragenyx Pharmaceutical RARE Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 606 | 951 |
| Property, plant, and equipment, net | 235 | 244 |
| Marketable securities | 144 | 57 |
| Intangible assets, net | 172 | 176 |
| Goodwill | 44 | 44 |
| Other assets | 63 | 60 |
| Total assets | $1,264 | $1,532 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY (DEFICIT) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's intangibles (net)?
- Ultragenyx Pharmaceutical (RARE) reported intangibles (net) of $172M in Q2 2026.
- How has Ultragenyx Pharmaceutical's intangibles (net) changed year-over-year?
- Ultragenyx Pharmaceutical's intangibles (net) decreased by 1.6% year-over-year, from $174.73M to $172M.
- What is the long-term trend for Ultragenyx Pharmaceutical's intangibles (net)?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's intangibles (net) has grown at a 6.1% compound annual growth rate (CAGR), from $131.11M to $176M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Ultragenyx Pharmaceutical's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude